YTHDF1 and acute myeloid leukemia: FTO inhibition + radiotherapy enhanced tumor control without worsening normal-tissue toxicity; reader targeting (YTHDF1/2) + RT or RT+ICB amplified STING–IFN-I signaling and T-cell priming; METTL3 inhibition combined with venetoclax overcame acquired resistance in AML.